source
- Capricor shares jump as FDA signals openness to review updated Duchenne therapyCapricor Therapeutics saw its stock rise sharply after CEO Linda Marbán told analysts that the FDA is willing to look at an amended filing for its Duchenne muscular dystrophy cell therapy, deramioc…
- Vaderis raises $152 million to launch late-stage trials of AKT inhibitor engasertib for rare bleeding disorderVaderis Therapeutics announced a $152 million Series B financing round, giving it sufficient capital to advance its experimental AKT-targeting drug, engasertib. The company has also begun late-sta…